Navigation Links
MDS Inc. Announces Normal Course Issuer Bid
Date:6/30/2008

TORONTO, June 30 /PRNewswire-FirstCall/ - MDS Inc. (TSX: MDS, NYSE: MDZ), a leading provider of enabling products and services to the global life sciences markets, announced today that the Toronto Stock Exchange (TSX) accepted the Company's Notice of Intention to make a normal course issuer bid for a one-year period.

The Notice provides that during the twelve months commencing July 3, 2008 and ending July 2, 2009, if deemed appropriate by the Chief Executive Officer and Chief Financial Officer of the Company, MDS may purchase up to 4,136,766 MDS Common shares on the Toronto Stock Exchange and the New York Stock Exchange. This represents approximately 5% of the public float. At June 20, 2008, there were 122,028,330 Common shares issued and outstanding and 82,735,313 Common shares in the public float. All shares purchased by MDS under this normal course issuer bid will be promptly cancelled. Daily purchases will be limited to 130,250 Common shares, other than block purchase exceptions.

Under the Company's previous normal course issuer bid, which began on July 3, 2007 and ends on July 2, 2008, MDS has purchased and cancelled 1,235,300 Common shares to date.

Since all purchases of MDS Common shares under the normal course issuer bid would be made on the open market, the Company is not in a position to know the identity of the parties from whom it may purchase Common shares. The Company believes that the purchase of outstanding Common shares at certain times during the normal course issuer bid period may enhance value for shareholders and is an appropriate use of funds.

This document contains forward-looking statements. Some forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "indicates" or similar expressions. The statements are not a guarantee of future performance and are inherently subject to risks and uncertainties. The Company's actual results could differ materially from those currently anticipated due to a number of factors, including, but not limited to, successful integration of structural changes, including restructuring plans, acquisitions, technical or manufacturing or distribution issues, the competitive environment for the Company's products, the degree of market penetration of the Company's products, and other factors set forth in reports and other documents filed by the Company with Canadian and US securities regulatory authorities from time to time.

About MDS

MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that provides market-leading products and services for the development of drugs and diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS Inc. has more than 5,500 highly skilled people in 29 countries. Find out more at http://www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.


'/>"/>
SOURCE MDS Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Medical Machines Online Announces the Overstock and Release of a New ECG Machine
2. BMP Sunstone Announces Official Launch of Ferriprox in PRC
3. Elsevier announces 2007 journal impact factor highlights
4. Response Biomedical Corporation Announces Strategic Partnership with Roche Diagnostics To Commercialize Cardiovascular Tests
5. Microsoft Announces Winners of the 2008 Pharmaceutical and Life Sciences Innovation Awards
6. Hologic, Inc. Announces Grant of Early Termination of Antitrust Waiting Period for Third Wave Technologies, Inc. Tender Offer
7. DST Systems, Inc. Announces Notification of Earnings Release Date
8. A Place for Mom, Nations Largest Assisted Living and Senior Housing Referral Service Announces New Vice President of Finance
9. LCA-Vision Announces CFO Change
10. BD Announces Live Webcast of Third Fiscal Quarter Earnings Conference Call
11. Bally Total Fitness Announces New Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its first-ever ... Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding work ... Practice and Pediatric Emergency Medicine Practice. , “With this award, we recognize ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology: